Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2118 January 2026

APPLICANT (stamp or sticker acceptable)			mp or stic	cker acceptable)	PATIENT NHI:	REFERRER Reg No:				
Reg No:					First Names:	First Names:				
Name:					Surname:	Surname:				
Address:					DOB:	Address:				
Addre	:55					Address.				
					Address:					
Fax N	lumbe	r:				Fax Number:				
Abira	atero	ne a	cetate							
Initial application Applications only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist or urologist. Approvals valid for 6 months.  Prerequisites(tick boxes where appropriate)  Patient has prostate cancer    Patient has metastases     Patient's disease is castration resistant     Patient has disease is castration resistant     Patient has disease progression (rising serum PSA) after second line anti-androgen therapy     Patient has ECOG performance score of 0-1     Patient has not had prior treatment with taxane chemotherapy containing a taxane     Patient has ECOG performance score of 0-2     Patient has not had prior treatment with abiraterone     Patient has not had prior treatment with abiraterone     Patient has not had prior treatment with abiraterone										
Curro Appl radia	ent ap	proval s only ncolog	Number from a n	(if known):	tion oncologist, urologist or medical practitioner on th or 6 months.	e recommendation of a medical oncologist,				
	and,	s	Significant decrease in serum PSA from baseline							
	No evidence of clinical disease progression									
	and	No initiation of taxane chemotherapy with abiraterone								
		П	The treatment remains appropriate and the nationt is benefiting from treatment							

I confirm the above details are correct and that in signing this form I understand I may be audited.

Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 2 Form SA2118 January 2026

Name:         Surname:         Surname:           Address:         DOB:         Address:           Address:	APPLIC	ANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:							
Address:	Reg No:		First Names:	First Names:							
Address:  Fax Number: Fax Number:  Abiraterone acetate - continued  Renewal — pandemic circumstances  Current approval Number (if known):	Name:		Surname:	Surname:							
Fax Number: Fax Number:  Abiraterone acetate - continued  Renewal — pandemic circumstances  Current approval Number (if known):	Address	:	DOB:	Address:							
Abiraterone acetate - continued  Renewal — pandemic circumstances  Current approval Number (if known):			Address:								
Abiraterone acetate - continued  Renewal — pandemic circumstances  Current approval Number (if known):											
Renewal — pandemic circumstances  Current approval Number (if known):	Fax Nur	nber:		Fax Number:							
Current approval Number (if known):	Abiraterone acetate - continued										
Applications from any relevant practitioner. Approvals valid for 6 months.  Prerequisites (tick boxes where appropriate)  The patient is clinically benefiting from treatment and continued treatment remains appropriate  Abiraterone acetate to be discontinued at progression  and  No initiation of taxane chemotherapy with abiraterone and	Renewal — pandemic circumstances										
Prerequisites(tick boxes where appropriate)  The patient is clinically benefiting from treatment and continued treatment remains appropriate  and Abiraterone acetate to be discontinued at progression and No initiation of taxane chemotherapy with abiraterone and	Current approval Number (if known):										
The patient is clinically benefiting from treatment and continued treatment remains appropriate  and Abiraterone acetate to be discontinued at progression and No initiation of taxane chemotherapy with abiraterone and	Applications from any relevant practitioner. Approvals valid for 6 months.										
and Abiraterone acetate to be discontinued at progression and No initiation of taxane chemotherapy with abiraterone and	Prerequisites(tick boxes where appropriate)										
Abiraterone acetate to be discontinued at progression  and  No initiation of taxane chemotherapy with abiraterone and	a										
No initiation of taxane chemotherapy with abiraterone		Abiraterone acetate to be disconting	Abiraterone acetate to be discontinued at progression								
		No initiation of taxane chemothera	No initiation of taxane chemotherapy with abiraterone								
			The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on the health sector								

I confirm the above details are correct and that in signing this form I understand I may be audited.